Just over a year ago, I wrote (rather extensively) on the European Commission’s public consultation entitled “Towards more effective EU Merger Control” in which the Commission proposed to (i) expand its powers to review non-controlling minority interests and (ii) streamline the case referral system between the European Commission and NCAs (see here).
Our regular readers will note that Mark Jones alerted them to the European Commission’s second public consultation on this subject (see here). As Mark noted, the deadline for this consultation closes on 3 October 2014.
The purpose of this post is not to repeat Mark’s (or indeed my prior 2013 post). Rather I thought that it may be useful to p [...]
9th GCLC Evening Policy Talk
Monday, September 29, 2014 from 18:45 PM to 20:30 PM
The Intel Judgment and the Administrability of the Effects-based Approach
Professor Massimo MOTTA, Chief Economist DG COMP
18:45 – 19:00: Registration
19:00 – 19:45: Talk
19:45 – 20:00: Question time
20:00 – 20:30: Cocktail
Location: The Hotel
38 Boulevard de Waterloo
For attending this event, please register HERE.
The event will take place under Chatham House rule.
Case for discussion:
T-286/09, Intel/Commission, Judgment of 12 June 2014.[...]
On 15 August 2014, the Competition and Markets Authority (“CMA”) approved Alliance Medical Group’s completed acquisition of IBA Molecular’s radioactive medical tracer business. Although IBA’s business was loss-making, would have exited the market and there was no other credible buyer for it, the CMA refused to apply the ‘failing firm’ (or ‘exiting firm’) defence, as it was not inevitable that, in the event of IBA’s exit, all or most of its existing customer contracts would have passed to Alliance. The CMA did, however, find that the merger did not substantially lessen competition, as there would remain two strong competitors, so ensuring continued customer choice.
On 9 July 2014, the European Commission published a White Paper setting out proposals to amend the EU merger control system. The proposed reform of the system is the most significant in the last 10 years and could have an impact on many corporate transactions.
The proposals deal with the following:
On 10 June 2014, the Polish Parliament adopted a significant set of amendments to the Polish Competition Law Act (the “Act”). Having received Presidential approval on 30 June 2014, the amended Act is now waiting for publication. The changes are expected to come into force relatively soon. The amendments will take effect 6 months after publication, which means that the new law will come into force at the beginning of 2015.
In this and subsequent posts, I would like to briefly analyze some of the most important changes, starting with the change that has been particularly hotly debated i.e. the introduction of the possibility to impose fines on individuals who manage undertakings which ent [...]
With the exception of hard-core cartel conduct such as price-fixing and bid-rigging, Canadian competition law has de-emphasized in recent years the importance of pricing conduct as a source of anti-competitive harm. Thus, although the Canadian Competition Act historically contained a variety of criminal offences targeted at pricing conduct – price discrimination, predatory pricing, geographic price discrimination, promotional allowances, and price maintenance – it was only the latter offence that attracted any material enforcement activity. The other pricing offences, although formally “on the books”, were rarely prosecuted, if at all.
It is not surprising, therefore, that [...]